Metastatic Melanoma Responds to First-Line Interleukin-21

This article originally appeared here.
Metastatic Melanoma Responds to First-Line Interleukin-21
Metastatic Melanoma Responds to First-Line Interleukin-21

(HealthDay News) -- In the first-line treatment of metastatic melanoma, interleukin-21 (IL-21) shows an overall response rate (ORR) of 22.5 percent and warrants further study, according to research published online Aug. 20 in the Journal of Clinical Oncology.

Teresa M. Petrella, M.D., of the Sunnybrook Odette Cancer Centre in Toronto, and colleagues conducted a phase 2, multicenter study to evaluate the efficacy and safety of IL-21 in patients with metastatic melanoma. Two of the groups received either 30 µg/kg per day (30 patients) or 50 µg/kg per day (three patients) by intravenous bolus for five days of each week during weeks one, three, and five of an eight-week cycle. A third group received 50 µg/kg per day (seven patients) for five days of each week during weeks one and three of a six-week cycle.

The researchers found that treatment-related adverse events included fatigue, rash, diarrhea, nausea, and myalgia. The ORR was 22.5 percent, with nine partial responses and 16 with stable disease. Median duration of response for all responders was 5.3 months. Response was not dependent on either BRAF mutation status or IL-21 receptor expression. Overall, median progression-free survival was 4.3 months and median overall survival was 12.4 months.

"Promising antitumor activity was observed at both doses and schedules used in this trial, although the numbers treated are too small for definitive comparisons to be made," the authors write. "Responses were seen at all disease sites, including skin, lymph nodes, lung, liver, and other visceral organs."

Two study authors disclosed receiving research funding from ZymoGenetics.

Full Text (subscription or payment may be required)

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs